Safe and Successful Treatment of Acute Cellular Rejection of an Intestine and Abdominal Wall Transplant With Vedolizumab

Graft survival rates after intestinal transplantation (ITx) are still the lowest in comparison to other solid organ transplants. One of the main reasons is the frequent occurrence of acute cellular rejection (ACR). Vedolizumab is an antibody against α4β7(+) integrin involved in gut-homing of T cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Trentadue, Guido, Kats-Ugurlu, Gursah, Blokzijl, Tjasso, Diercks, Gilles FH, Haveman, Jan Willem, Faber, Klaas Nico, Dijkstra, Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Intestinal Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004630/
https://www.ncbi.nlm.nih.gov/pubmed/32095513
http://dx.doi.org/10.1097/TXD.0000000000000973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004630/
https://www.ncbi.nlm.nih.gov/pubmed/32095513
http://dx.doi.org/10.1097/TXD.0000000000000973

Ejemplares similares